ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

ClinicalTrials.gov ID: NCT07183709

Public ClinicalTrials.gov record NCT07183709. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 8:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1 Dose Ranging Study to Assess the Safety, Reactogenicity, and Immunogenicity of PepGNP-COVID19, a Synthetic Nanoparticle-based, T Cell Priming Peptide Vaccine Against SARS-CoV-2 As a Booster Dose

Study identification

NCT ID
NCT07183709
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
60 participants

Conditions and interventions

Conditions

Interventions

  • PepGNP-COVID19 Biological
  • Sterile Water for Injection Other

Biological · Other

Eligibility (public fields only)

Age range
18 Years to 64 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 1, 2026
Primary completion
Oct 17, 2026
Completion
Oct 17, 2026
Last update posted
May 14, 2026

2026

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
University of Alabama at Birmingham School of Medicine - Infectious Disease Birmingham Alabama 35222
George Washington University Medical Faculty Associates Washington D.C. District of Columbia 20037-3201
Cincinnati Children's Hospital Medical Center Vaccine Research Center Cincinnati Ohio 45229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07183709, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 14, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07183709 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →